Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Biogen Earnings: What To Look For From BIIB

July 29, 2025 at 23:06 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

BIIB Cover Image

Biotech company Biogen (NASDAQ: BIIB) will be reporting results this Thursday morning. Here’s what you need to know.

Biogen beat analysts’ revenue expectations by 8.6% last quarter, reporting revenues of $2.43 billion, up 6.1% year on year. It was a satisfactory quarter for the company, with a decent beat of analysts’ EPS estimates but a slight miss of analysts’ full-year EPS guidance estimates.

Is Biogen a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Biogen’s revenue to decline 5.6% year on year to $2.33 billion, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $3.88 per share.

Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 8 downward revisions over the last 30 days (we track 24 analysts). Biogen has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Biogen’s peers in the biotechnology segment, only Incyte has reported results so far. It beat analysts’ revenue estimates by 5.5%, delivering year-on-year sales growth of 16.5%.

Read our full analysis of Incyte’s earnings results here.

Investors in the biotechnology segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. Biogen is up 3.4% during the same time and is heading into earnings with an average analyst price target of $168.85 (compared to the current share price of $129.80).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article